BRIDGE MEDICINES
Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes an unbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases.
BRIDGE MEDICINES
Industry:
Pharmaceutical
Founded:
2016-01-01
Address:
Sioux Falls, South Dakota, United States
Country:
United States
Website Url:
http://www.bridgemedicines.com
Total Employee:
11+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress Wordpress Plugins Nginx Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Cyagen Biosciences
Cyagen Biosciences is an emerging and innovative biotechnology company.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montrรฉal and Lรฉvis.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Employees Featured
Investors List
Takeda
Takeda investment in Venture Round - Bridge Medicines
Bay City Capital
Bay City Capital investment in Venture Round - Bridge Medicines
Deerfield
Deerfield investment in Venture Round - Bridge Medicines
Deerfield
Deerfield investment in Venture Round - Bridge Medicines
Bay City Capital
Bay City Capital investment in Venture Round - Bridge Medicines
Takeda
Takeda investment in Venture Round - Bridge Medicines
Official Site Inspections
http://www.bridgemedicines.com Semrush global rank: 6 M Semrush visits lastest month: 1.36 K
- Host name: 209.182.198.166
- IP address: 209.182.198.166
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Bridge Medicines"
About โ Bridge Medicines
ABOUT US Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare โฆSee details»
Bridge Medicines - Crunchbase Company Profile
Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill โฆSee details»
Bridge Medicines - PitchBook
Bridge Medicines General Information Description. Operator of a biotechnology company intended to focus on the treatment of human diseases through drug โฆSee details»
Bridge Medicines LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Bridge Medicines LLC of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Bridge Medicines LLC - LinkedIn
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and ...See details»
Bridge Medicines โ Accelerating the Path to the Patient
Sep 21, 2020 MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical โฆSee details»
Bridge Medicines - Biotech Careers
Bridge Medicines is a fully funded, professionally staffed biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell โฆSee details»
Bridge Medicines company information, funding & investors
Bridge Medicines is a biopharmaceutical company focused on advancing breakthrough therapeutics for difficult-to-treat cancers. The company operates in the life sciences sector, โฆSee details»
Bridge Medicines: Revenue, Worth, Valuation & Competitors 2025
About Bridge Medicines. Bridge Medicines is a Pharmaceuticals related company founded in 2016 and based in New York City with 2 employees an estimated revenue of $402K, and. It has 10 โฆSee details»
Bridge Medicines LLC Information - RocketReach
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company โฆSee details»
Bridge Medicines Announces Additional Funding of $10 Million โฆ
Nov 12, 2020 For more information about Bridge Medicines, please visit www.BridgeMedicines.com. Contact: Matt Stroschein Jacob S. Lasdon House, 5 th Floor 420 โฆSee details»
Bridge Medicines - Overview, News & Similar companies - ZoomInfo
Nov 11, 2020 www.bridgemedicines.com. Revenue $5.2 Million. Industry Pharmaceuticals Healthcare . Recent News & Media. Bridge Medicines Enters Exclusive License Agreement โฆSee details»
Team โ Bridge Medicines
Bobb has approximately 22 years as an office professional with expertise in organization and coordination of multiple activities and special projects that demand strict quality guidelines and โฆSee details»
Bridge Medicines LLC โ Funding, Valuation, Investors, News
Aug 30, 2022 Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda โฆSee details»
Bridge Medicines | VentureRadar
Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from... ... Find out more ...See details»
Contact โ Bridge Medicines
Accelerating the Path to the Patient HEADQUARTERS Jacob S. Lasdon House 420 East 70th Street, Suite 510 New York, NY 10021 GENERAL INQUIRIES [email protected]See details»
Bridge Medicines LLC (Bridge Medicines LLC) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธด โฆ
Galecto will acquire the global rights to BRM-1420 from Bridge Medicines, the company announced this week. BRM-1420, a dual ENL-YEATS and FLT3 inhibitor that has shown โฆSee details»
Bridge Medicines | Newsroom
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I โฆSee details»
Partners โ Bridge Medicines
The doctors and scientists of Weill Cornell Medicineโfaculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician โฆSee details»
Pipeline - Bridge Medicines
Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine. By eliminating roadblocks like loss of control of โฆSee details»